Signed a non-disclosure agreement (NDA) with a US company with sales of 400 trillion won in 2024 and a Chinese company with sales of 1.2 trillion won, and negotiated exclusive rights and strategic collaborations.

U.S. Company C, with expected sales of KRW 400 trillion in 2024, and Chinese Company M, with KRW 1.2 trillion in sales, highly valued Anyfusion's future market potential and signed a Non-Disclosure Agreement (NDA) and are negotiating a comprehensive global business partnership based on a strategic partnership encompassing exclusive distribution rights, joint R&D, insurance listing, and production.

Given the diverse healthcare policies and environments of each country, we are pursuing product development, certification, insurance listing, and marketing strategies optimized for each market. Following these efforts, we are rapidly targeting North America, which accounts for approximately 40% of the global healthcare market, Japan, China, Australia, and New Zealand, which account for 25%, and Europe, which accounts for 20%. Through consultation and negotiation with these companies, we aim to establish Anyfusion as a flagship product in key global healthcare markets, with products based on the Anyfusion platform, which has been in use for over a century, from human-operated, non-closed analog syringes to machine-operated, closed digital syringes. The world's only low-cost, highly efficient national health insurance system, with its focus on hospitalization, surgery, and medication, has led to a world-class medical environment. However, this burden on medical professionals has inevitably led to a poorly structured healthcare environment. Early access to this real-world experience in Korea will provide a competitive edge in ophthalmology and ophthalmology technologies for global market entry.

By securing competitiveness through domestic real-world experience and strategically leveraging the synergies of Anyfusion platform items, we aim to identify the business strategies and policies of partners currently negotiating in the conservative global healthcare market. We will then contract with the optimal partner and accelerate global commercialization.

We will do our best to establish our presence as a future growth engine for this new industry.

Thank you.